Strategic partnerships Pharma licensing and co-development partnerships present a clear avenue to accelerate Phase 3 trials for topical and inhaled pravibismane, leveraging external funding, clinical capabilities, and broader commercial reach.

Expanded indications There are opportunities to license or co-develop additional indications such as immunomodulation and inflammation, enabling rapid portfolio expansion beyond current diabetic foot ulcers, orthopedic infections, and NTM lung diseases.

Public funding leverage With over 22 million in grants and notable government support, pursue grant-backed collaborations or milestone-driven deals to de-risk development costs and extend the reach of pravibismane into new markets.

Strategic buyers Mid-to-large biotech or specialty pharma with infectious disease, antibiofilm, or anti-inflammatory franchises could be interested in acquiring or partnering to access a first-in-class agent with multiple delivery modalities.

Clinical execution support Target CROs, academic consortia, and government programs to bolster Phase 3 execution and inhaled formulation development, presenting a compelling case to partners seeking to accelerate timelines and share risk.